Live Breaking News & Updates on Colon In Continuity

Stay updated with breaking news from Colon in continuity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ironwood's apraglutide wins in short bowel but CIC questioned

Positive phase III data from Ironwood Pharmaceuticals Inc. with once-weekly glucagon-like peptide-2 analogue apraglutide failed to impress Wall Street, and shares of the Boston-based firm (NASDAQ:IRWD) closed Feb. 29 at $9.43, down $5.69, or 37.6%. The experiment called Stars tested apraglutide to reduce parenteral support in adults with short bowel syndrome with intestinal failure. Rare and severe, the condition affects about 18,000 adults in the U.S., Europe and Japan. Based on the latest data, Ironwood plans to submit an NDA to the U.S. FDA and other regulatory filings. ....

United States , Ironwood Pharmaceuticals Inc , Ironwood Pharmaceuticals , Wall Street , Ironwood Pharmaceuticals Inc , Short Bowel Syndrome , Glucagon Like Peptide 2 Analogue , Glp 2 , Colon In Continuity ,

Apraglutide Reduces Parenteral Support Dependency in Patients with SBS-IF, CIC

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support. ....

Linkedin Tim Vanuytsel , Tim Vanuytsel , Ironwood Pharmaceuticals Presents Positive Final Data , Transplantation Center , Ironwood Pharmaceuticals , United European Gastroenterology Week , Leuven Intestinal Failure , Short Bowel Syndrome , Intestinal Failure , United European Gastroenterology , Vectivbio Reports Positive Interim Clinical Data , Investigating Apraglutide , Intestinal Failure Patients , Balance Study , Patients With , Stars Nutrition , Phase 2 , Parenteral Support , Sbs If , Colon In Continuity , Glp 2 ,